

**12<sup>th</sup> May 2022**

**Present:** Louise Brown, Professional Manager Pharmacy Services, Acute and Regional  
Karen Devenney, Senior Manager, Nursing, Quality and Patient Safety  
Eimear McCusker (Co-chair), Head of Pharmacy and Medicines Management  
Clare McMahon, Head of Resource Utilisation  
JD Mullan, Professional Manager Pharmacy Services, Acute and Regional  
Eamon Mullaney, Professional Manager Pharmacy Services, BHSC Medicines  
Procurement & Regional Pharmacy Manufacturing Services  
Sharon O'Donnell, Lead Medication Safety Pharmacist  
Aideen O'Kane, Encompass Lead Pharmacist  
Cathy Woods, Interim Service manager/Senior Nurse, Community Sites

[illegible]

	<p><b>vii. Pharmacy Computer system (A O’Kane)</b> Aideen O’Kane’s meeting with Mark Cross and Philip Toner on this issue was cancelled and is to be rescheduled. Aideen will follow up and arrange a new date.</p> <p><b>viii. Medicines Optimisation Committee Terms of reference (E McCusker)</b> Included for information; updated with comments received.</p>	<b>A O’Kane</b>
<b>3.</b>	<p><b>Encompass</b></p> <p>Eimear welcomed Aideen O’Kane in her new role as Encompass Lead Pharmacist. Aideen will provide updates at the meetings in future. Karen Devenney reported that no Lead Nurse for Encompass has been appointed yet.</p>	
<b>4.</b>	<p><b>Medicines Optimisation dashboard/subcommittee updates</b></p> <p>Eimear requested that the formal reports from the groups that are sent to her be signed off by the Chair of the group.</p> <p><b>i. Medicines Risk and Safety Assurance Group (M Cross)</b> Group looking at issues around eTANs. Since the last meeting, Sharon, Louise and some other attended a meeting with the Board about this. There are issues around this in Primary Care where some practices can’t or won’t use the electronic document transfer. The GP adviser flags these issues up with the practices when they arise. Another issue the group were looking at was clozapine refusals.</p> <p>Eimear asked why some meetings have been cancelled and Sharon reported that there was no Chair for those meetings. Eimear advised that a Co-Chair be appointed to prevent this happening again. Dr. Cross is seeking nominations for a Co-Chair for the group but has been unsuccessful so far.</p> <p>Nothing to report on the Medication Safety Thermometer, it will be brought to the next meeting.</p> <p><b>ii. Medicines Optimisation Efficiency programme</b> The target for the Trust was £3.758 million and £2.022 Million was achieved, so there was a shortfall of around 1.7 million. Any new savings made in this financial year will go first against the shortfall from the previous year. Eamon Mullaney and Clare McMahon have a meeting arranged to look at the targets for 2022/23. Paediatric gastroenterology are moving to biosimilars and there is a 10% investment to support that switch.</p> <p><b>iii. Efficiencies/Biosimilars (E Mullaney/C McMahon)</b> The areas that Eamon will be looking at next for the biosimilars is paediatric gastroenterology and also ophthalmology. They are currently on their third biosimilar switch.</p> <p>Eimear reported that at the QMS presentation to the Executive team, Cathy Jack picked up on the biosimilars and the differences between the Trusts. Eimear explained that it was to do with the size and complexity of Belfast Trust in relation to the other Trusts. Cathy Jack has asked for a breakdown of biosimilar switches by speciality for the next QMS presentation.</p>	

	<p>iv. <b>D&amp;T/New Drugs Committee (M Cross)</b> Nothing new to progress outside formal report submitted.</p> <p>v. <b>Non Medical Prescribing (E McCusker)</b> AHP – 29 non-medical prescribers, 206 Nurses, 15 optometrists and 56 Pharmacists. Currently progressing the renewal process, however the Hub has changed to the Loop and Eimear has lost her editing rights so this needs to be rectified. Non-Medical prescribing policy also being updated and it will be brought to D&amp;T in the next month.</p> <p>vi. <b>Medical gas committee (E Mullaney)</b> Eamon has devised an eLearning training package to try to solve the issue of poor attendance at the training sessions.</p> <p>vii. <b>Immunoglobulin sub-committee (JD Mullan)</b> JD spoke to James Taggart regarding this and he reported that there has been an increase in the amount of immunoglobulins in quarter 4 in comparison to quarter 3. This could be due to a backlog of invoices that have just been passed. There is full accountability of where these have been used and the indications.</p>	
5.	<p><b>AOB</b></p> <p>Eimear asked JD with regards to the MIG plan. JD reported that the workplan was brought to D&amp;T and that meetings will take place in the next few weeks. D&amp;T approved this plan.</p> <p>Chris Hagan has been in contact with Eimear with regards to the MIG plan and reported that the Trust Primary Care Medicines Management will be meeting soon. Mr Hagan has asked that they consider the Encompass reports and all the areas where the prescribing is different from the rest of the UK as part of the report.</p>	
6.	<p><b>Date &amp; Time of Next Meeting: Sept 23<sup>rd</sup> 2022 at 11:00</b></p>	